Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations

PURPOSE: Subsets of non-small-cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first-generation EGFR-tyrosine kinase inhibitors (TKIs; erlotinib, gefitinib, and icotinib) in patients with non-small-cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dan, Song, Zhengbo, Cheng, Guoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944908/
https://www.ncbi.nlm.nih.gov/pubmed/27468240
http://dx.doi.org/10.2147/OTT.S108242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944908/
https://www.ncbi.nlm.nih.gov/pubmed/27468240
http://dx.doi.org/10.2147/OTT.S108242

Ejemplares similares